timothy sykes logo
QNRX Surges As Quoin’s QRX003 Data And $50M Raise Shift Outlook Thumbnail
G Google News

QNRX Surges As Quoin’s QRX003 Data And $50M Raise Shift Outlook

TIM SYKES•UPDATED AUG. 29, 2026, 11:05 AM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Quoin Pharmaceuticals Ltd. stocks have been trading up by 10.65 percent following positive trial progress and regulatory momentum.

Market Insights For QNRX Traders

  • Quoin Pharmaceuticals reported statistically significant, positive interim Phase 2/3 data for QRX003 in Netherton Syndrome, with strong efficacy, itch reduction in the most symptomatic patients, and a clean safety profile.
  • QRX003 could become the first FDA-approved treatment for Netherton Syndrome, with full trial enrollment expected by the end of 2026 and topline data anticipated in 2027/04/01–2027/06/30.
  • The company is raising up to $50M in a private placement at $4.88 per unit, with warrants exercisable at $6.10, extending cash runway into 2H 2029 but adding dilution risk.
  • Following the data and financing news, shares of Quoin Pharmaceuticals jumped roughly 18%–29%, signaling strong bullish sentiment and elevated trading interest in QNRX.
  • In Q2 2026, Quoin reported a wider loss as R&D spending increased, while securing FDA conditional brand-name approval for QRX003 (QYLEKI) and advancing additional rare-dermatology programs.

Candlestick Chart

Weekly Update Aug 24 – Aug 28, 2026: On Saturday, August 29, 2026 Quoin Pharmaceuticals Ltd. stock [NASDAQ: QNRX] is trending up by 10.65%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Quoin Pharmaceuticals (QNRX) remains a high‑risk, binary-outcome rare-dermatology platform story with weak fundamentals. Q3 2025 data show zero revenue, deeply negative margins, and ROE below -500%, underscoring a value-destruction profile typical of micro-cap pre-commercial biotech. Operating cash burn of ~$2.2M per quarter against ~$1.8M cash and negative equity highlights balance sheet fragility, though the recent up-to-$50M private placement at $4.88 materially extends runway and partially offsets going-concern risk.

Technically, QNRX has flipped from a low-liquidity grind to a momentum breakout following the positive QRX003 data and financing. The weekly tape shows a sharp move from ~5.0 to an intraday high of 6.32 on 8/28, with a closing pullback to 5.70, indicating aggressive profit taking but sustained interest above the deal price. Dominant trend is now short-term bullish; $4.90–5.00 (deal floor) is the critical actionable support level for entries and risk management.

Near-term catalysts are dominated by QRX003’s statistically significant interim Phase 2/3 data in Netherton Syndrome, conditional brand-name approval (QYLEKI), and expansion into Peeling Skin Syndrome plus the QRX009 platform. These place QNRX ahead of most micro-cap dermatology peers on clinical differentiation but behind larger biotech benchmarks on diversification and profitability. With cash likely extended into 2H 2029 post-financing, risk-reward is favorable: I see asymmetric upside with a 6–7 near-term trading band, using 4.90 as hard support.

More Breaking News

Quick Financial Overview

Quoin Pharmaceuticals Ltd. (QNRX) just delivered the classic small-cap biotech one-two punch: strong clinical data and fresh capital. Interim Phase 2/3 results for QRX003 in Netherton Syndrome showed statistically significant efficacy, with 4 of 6 patients hitting the primary IGA endpoint plus key secondary measures and meaningful itch reduction. For traders, that is a major de-risking event on the way to potential first-to-market status in this rare disease.

On the tape, QNRX has reacted with sharp momentum. The weekly data show price pinned around the low-$5 area early in the week, then spiking as high as the low-$6 range once the news hit, with the week closing meaningfully above the prior $5 handle. Intraday, a 5-minute bar with a $7.22 open and $8.25 high before fading toward the low-$6s tells you everything about current character: gap, squeeze, then profit-taking as short-term traders lock gains.

Under the hood, Quoin is still a development-stage, loss-making biotech. The latest quarterly report shows net income around -$3.95M, driven largely by R&D of about $2.28M and G&A of roughly $1.74M. Operating cash flow was about -$2.23M, with free cash flow at a similar negative level and cash of roughly $1.8M at period end, before the new raise. Key ratios highlight pressure: return on equity and return on assets are deeply negative, while book value per share sits near $1.96 with price-to-book around 2.6, underscoring that traders are paying up for pipeline potential, not current earnings power.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”